Chicago, May 21, 2026 (GLOBE NEWSWIRE) -- Kooth Digital Health announced the appointment of Fred Bendana as Chief Commercial Officer, a role that will accelerate the growth of Soluna, Kooth's digital mental health platform purpose-built for young people in the U.S., and advance the company's commercial strategy across the United States and the United Kingdom.

Benda?a brings nearly a decade of executive leadership experience from The Cigna Group, where he held senior roles within Evernorth Health Services and Express Scripts pharmacy benefits. He has led sales, business development, and growth teams across complex healthcare markets, serving government, health plan, and employer clients with solutions spanning behavioral health, virtual care, pharmacy, medical, and care delivery.

"Fred joins us at a genuinely significant moment," said Kate Newhouse, Chief Executive Officer of Kooth. "For 25 years, Kooth has existed to solve a problem that traditional mental health systems have struggled to address: how to reach people who need support but cannot access it. Today, we serve over 20 million people across the US and UK, embedded in state and national infrastructure, and backed by independent evidence of impact that I believe is unmatched in our sector. That scale brings both opportunity and responsibility. Our commercial model - whether working with state governments in the US, commissioners and health systems in the UK, or expanding relationships with counties, universities, managed care organizations, and payers - demands patient, systems-literate leadership that can navigate complexity while building the long-term partnerships on which durable growth depends. Fred brings precisely that. His appointment reflects our confidence that the next phase of Kooth's growth, on both sides of the Atlantic, will be built on the same foundations that have defined the last 25 years - trust, evidence, and a genuine commitment to the people we serve."

Benda?a's appointment comes as Kooth continues to expand Soluna's reach across the US and UK, deepening partnerships with state governments, national health systems, payers, schools, and community organisations. Soluna is already one of the largest and most clinically validated youth mental health platforms in the world, serving millions of young people and operating at a scale few organisations in this space have achieved - with independent evaluation demonstrating measurable, population-level impact. The company sees significant runway ahead as demand for early, accessible mental health support continues to outpace supply on both sides of the Atlantic.

"Kooth has built something genuinely rare; a platform that young people trust, that commissioners and government partners rely on, and that has the clinical evidence to back it up," said Benda?a. "That combination doesn't come along often. The opportunity to expand access and the urgency to do so has never been greater. Young people who get the right support earlier stay in school, enter the workforce, contribute to their communities, and ultimately help build stronger economies. The individual and downstream impact is what drives us."

"Fred's appointment reflects the board's conviction that Kooth is entering a new phase of commercial maturity," said Peter Whiting, Chair of the Board of Kooth Digital Health. "He brings the depth of experience and strategic clarity needed to accelerate our growth across both the US and UK. We are delighted to welcome him to the team."

About Kooth Digital Health: Kooth is a global leader in digital mental and behavioral health, providing safe, effective care to over 20 million people. For 25 years, Kooth has pioneered scalable solutions that deliver immediate, direct, universal access to mental health support. Kooth holds URAC accreditation in the US and is the longest standing digital mental health provider to hold UK-wide accreditation from the British Association of Counselling and Psychotherapy (BACP), validating a commitment to quality, safety, and accountability across both markets. Learn more at connect.kooth.com. 

Madison Hamilton

Kooth

mhamilton@kooth.com

Copyright 2026 GlobeNewswire, Inc.

Recognition reflects TDCX's evolution into a global firm helping clients navigate digital and AI transformation with a combination of human expertise, intelligent technology, and operational precision

SINGAPORE - Media OutReach Newswire - 22 May 2026 - TDCX, a leading global customer experience (CX) solutions firm, has been named to the Outsource Accelerator (OA) 500 2026 Index Top 50, marking its fourth consecutive year on Outsource Accelerator's global ranking of leading business process outsourcing firms. The OA500 evaluated 3,369 BPO companies worldwide across more than 20 performance metrics over a 15-month assessment period, drawing on independent data sources including Crunchbase, Glassdoor, LinkedIn, and ZoomInfo.

The recognition comes in TDCX's 30th anniversary year and seven months after the company unveiled its refreshed brand and Enable the Future positioning. The new identity reflects TDCX's evolution into a global firm helping clients navigate digital and AI transformation with a combination of human expertise, intelligent technology, and operational precision.

Mr. Laurent Junique, founder and CEO of TDCX, said: "Outsourcing is shifting from cost arbitrage to capability arbitrage. The companies that win in this market will be the ones that combine deep human expertise with intelligent technology, and bring them together with judgment. Four consecutive years in the OA500 Top 50 says TDCX is doing that in a way the market recognizes."

Mr. Derek Gallimore, founder and CEO of Outsource Accelerator, said: "TDCX's fourth consecutive year in the OA500 Top 50 reflects something rare in this industry: sustained, disciplined execution paired with real strategic evolution. They've moved decisively beyond traditional CX into digital and AI-enabled service for some of the world's most demanding brands. As outsourcing shifts from headcount to outcomes, TDCX is one of the operators best placed to lead that transition."

The OA500 Index assesses BPO firms across criteria including global delivery footprint, online presence, employee sentiment, LinkedIn engagement, third-party analyst data, and operational benchmarks. With more than 20,000 employees across 37 campuses spanning Asia, Europe, and the United States, TDCX serves clients in digital advertising and social media, e-commerce, fintech, gaming, healthtech, media, technology, and travel and hospitality.

About TDCX

Singapore-headquartered TDCX is a leading global customer experience solutions firm that provides customer experience (CX) solutions, sales and digital marketing services, and content moderation for clients across various industries. These include digital advertising and social media, e-commerce, fintech, gaming, healthtech, media, technology and, travel and hospitality.

With a focus on helping companies enable the future, TDCX's smart, scalable approach, driven by innovation and operational precision, positions it as a key partner for companies targeting tangible outcomes. With more than 20,000 employees across 37 campuses worldwide, TDCX provides its clients with comprehensive coverage in Asia, Europe and the United States.

For more information, please visit www.tdcx.com.

The issuer is solely responsible for the content of this announcement.

Hashtags: #TDCX #OA500 #CX #Outsourcing #EnableTheFuture

HOHHOT - Media OutReach Newswire - 22 May 2026 - From May 17 to 19, 2026, Hohhot, Inner Mongolia, proudly hosted the China main venue event for International Museum Day, centered around the theme "Museum: A Bridge Connecting the World." Situated at the eastern gateway of the Grassland Silk Road and a key point along the Ancient Tea Horse Road, Hohhot has long served as a vital commercial and cultural crossroads linking the grasslands with China's Central Plains, as well as connecting China with Russia, Mongolia, and the broader Eurasian region.

Historically a hub for East-West cultural exchange, Hohhot continues to play a significant role as a northern gateway in China's opening-up strategy. By hosting this prestigious national cultural event, China reaffirms its commitment to fostering intercultural dialogue through museums, enhancing the sense of shared identity among the Chinese people, and promoting mutual learning and exchange between China and the international community.

May 18, the opening ceremony of the main venue was held at the Inner Mongolia Museum, attracting a large gathering of people from all walks of life with enthusiastic responses. Photo by Zhang Zihe

The event was jointly organized by the National Cultural Heritage Administration and the People's Government of Inner Mongolia Autonomous Region. It brought together over 500 participants, including leaders from the museum and cultural heritage sectors, experts, scholars, and international guests, to explore innovative directions for museum development.

In recent years, Hohhot's museum sector has experienced rapid growth, marked by continuous enhancements in public cultural service capabilities. The city has established a well-planned and distinctive museum system. The Hohhot Museum has pioneered a "one main museum with six branches" model, integrating premier institutions such as the Zhaojun Museum and the General's Yamen. This approach has enabled the city to consistently present high-quality exhibitions, positioning museums as vital platforms for showcasing the cultural exchanges and integration among diverse ethnic groups, as well as promoting China's rich traditional heritage.

The opening ceremony on May 18 at the Inner Mongolia Museum highlighted China's museum achievements since the 14th Five-Year Plan, shared key cultural heritage updates, and emphasized museums' role as bridges connecting history and the present, China and the world, and the hearts of all ethnic communities.

During the event, three major exhibitions were launched simultaneously. The Heaven and Earth in Harmony: Exhibition of Ancient Chinese Music Culture, the Rivers and Mountains Shining: The Historical and Cultural Display of Hohhot, and the Radiance of Gold and Jade: Colorful China. Featuring nearly 300 exquisite bronze, gold, jade, and stone artifacts from numerous cultural institutions nationwide, these exhibitions span 8,000 years of heritage and vividly illustrate the rich diversity and unity of Chinese civilization, as well as the history of ethnic integration and coexistence.

One of the exhibits in the Radiance of Gold and Jade: Colorful China temporary exhibition hall at the Inner Mongolia Museum

Alongside the exhibitions, main and youth forums convened domestic and international experts and scholars to engage in in-depth discussions on industry development, international collaboration, and related topics, infusing fresh insights and youthful enthusiasm into the ongoing advancement of museums. On the evening of the 18th, the "Museum Night" immersive performance debuted at Dazhao Square, blending ethnic art, intangible cultural heritage skills, and light and shadow effects to vividly showcase the captivating fusion of the three major cultures of the grasslands, the Yellow River, and the Great Wall.

Building on the momentum of the main event, Hohhot also launched the 2026 "Museum Season," featuring a series of exhibitions, educational tours, and cultural tourism routes extending through the National Day holiday. This initiative fosters deeper integration between cultural heritage and the tourism industry, making cultural treasures more accessible to the public.

From its historic role as a hub on the Grassland Silk Road to its current status as a platform for civilizational dialogue, Hohhot's high-caliber cultural offerings showcase the unique qualities and openness of Chinese civilization. The city's museums truly serve as enduring bridges connecting China with the world and facilitating meaningful global exchanges.

The issuer is solely responsible for the content of this announcement.

NANNING, CHINA - Media OutReach Newswire - 21 May 2026 - The China-ASEAN Business and Trade Information Platform was officially launched in Nanning, Guangxi Zhuang Autonomous Region on Tuesday.

The platform offers comprehensive information services and an international communication platform to support economic and trade cooperation between China and ASEAN countries.

Built and operated by China News Network, the official website of China News Service, the platform serves as ASEAN trade agencies, industry associations, overseas Chinese communities, and cross-border enterprises, providing one-stop trade information services.

China News Service will leverage its strengths to build the China-ASEAN Business and Trade Information Platform into an influential and dynamic communication channel that promotes information sharing and provides services, to facilitate trade and people-to-people exchanges between China and ASEAN countries.

Currently, a trade information network between China and ASEAN countries has been built, with key content covering policy explanations, market conditions, investment promotion, business cooperation, and industry analysis, to comprehensively support cross-border trade activities.

Prior to the platform's launch, representatives from government departments, media outlets, research institutes, and universities in China and multiple ASEAN countries participated in discussions on economic and trade information exchange between China and ASEAN countries, as well as the development of the platform.

Consular officials from ASEAN member states including Cambodia, Myanmar, and Vietnam, stationed in Nanning expressed their hopes for enhancing China-ASEAN economic and trade connectivity as well as people-to-people ties through information sharing.

Against the backdrop of the signing of the China-ASEAN Free Trade Area 3.0 Upgrade Protocol, the platform serves as an information bridge for expanding cooperation, promoting trade, enhancing industrial upgrade, and achieving mutual benefits and win-win outcomes, they said.

They hope that the platform will play a greater role in trade facilitation and logistics services, empowering micro, small and medium-sized enterprises (MSMEs), and investment policies and regulatory measures, while helping share cooperation stories between China and ASEAN countries.

The issuer is solely responsible for the content of this announcement.

Hashtags: #Nanning

*The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.

*If approved, (TEV-'749) could help fill a significant unmet need in available schizophrenia treatment options by addressing the lack of a viable long-acting olanzapine formulation.

*Teva is committed to advancing this innovative treatment option, strengthening its scientific leadership in complex neurological conditions as part of its Pivot to Growth strategy.

TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-'749) for the treatment of schizophrenia in adults. (TEV-'749) aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.1

"Treatment adherence remains a challenge for people living with schizophrenia including those who rely on oral forms of Olanzapine. (TEV-'749), our investigational subcutaneously delivered olanzapine LAI, has the potential to help provide stability by offering the proven efficacy and safety of olanzapine as a once-every four weeks treatment," said Eric Hughes, MD, PhD, Executive Vice President, and Chief Medical Officer at Teva. "For too long, treatment options have been limited by the lack of a viable long-acting olanzapine formulation, and we look forward to working with the EMA to help address this gap in care."

"Daily oral olanzapine is one of the most commonly prescribed antipsychotics in Europe for people living with schizophrenia, and long-acting injectables are already well established in managing serious psychiatric conditions across the region," said Christophe Douat, CEO of Medincell. "We believe a practical long-acting olanzapine option that fits more naturally into patients' lives can help address a real and persistent need in schizophrenia."

Schizophrenia affects 0.3 - 1.5% of the population in Europe2, yet those living with the condition often face profound challenges of social isolation, unstable employment 3, and a life expectancy reduced by 15-20 years 4.

(TEV-'749) is not approved by any regulatory authority worldwide at this time. The submission to the EMA is supported by an extensive clinical development program, including the Phase 3 SOLARIS study. Across clinical development, (TEV-'749) demonstrated efficacy, a systemic safety profile, and exposure consistent with oral olanzapine.

(TEV-'749) utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled, steady, prolonged release of olanzapine.

About Schizophrenia

Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.2 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.2,3,4 Approximately 1% of the world's population will develop schizophrenia in their lifetime, and 0.3 - 1.5% of the population in Europe are currently diagnosed with the condition.3,4 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.4 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.4 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.5,6,7 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.2,3,4,5,6,7

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Media Inquiries:

Comms@tevaeu.com

Teva Investor Relations Inquiries:

TevaIR@tevapharm.com

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY (BEPO technology is licensed to Teva under the name SteadyTeq?). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

Medincell Media Inquiries:

Contact: communication@medincell.com

Teva Cautionary Note Regarding Forward-Looking Statements

This Press Release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "intend," "plan," "believe," "aim" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop olanzapine LAI TEV-'749 for the treatment of adult patients diagnosed with schizophrenia and to obtain regulatory approvals; our ability to successfully compete in the marketplace, including our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References

__________

1 Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

2 European Brain Council. Rethinking Schizophrenia. 2024. Available at https://www.braincouncil.eu/projects/rethinking-schizophrenia/#:~:text=Rethinking%20Schizophrenia%20is%20a%20research,that%20of%20the%20general%20population. Last accessed March 20263 Teva What lies beneath: Uncovering the hidden drivers and impact of Stigma in Schizophrenia White Paper 2025. Available at https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva-white-paper-uncovering-hidden-drivers-and-impact-stigma-in-schizophrenia.pdf Last accessed March 2026

4 Thornicroft G. British Journal of Psychiatry. 2011;199(6):441-442.

Copyright 2026 GlobeNewswire, Inc.

2026 programme expands to celebrate more communities, at more races, with more donations and the chance for fans to get involved

F1AGCA Winner - FORMULA 1 LENOVO GRAND PRIX DU CANADA 2026

The first F1 Allwyn Global Community Award of the 2026 season trophy was awarded to representatives from the winning local community initiative La Tabl?e des Chefs at the FORMULA 1 LENOVO GRAND PRIX DU CANADA 2026 in Montreal, Canada

F1AGCA_Canada_winner_8

MONTREAL, May 21, 2026 (GLOBE NEWSWIRE) -- La Tablee des Chefs has been named the first winner of the 2026 F1 Allwyn Global Community Award, at the FORMULA 1 LENOVO GRAND PRIX DU CANADA. The charity has been awarded a EUR100,000 donation from Allwyn, the lottery-led entertainment company, to further its mission to provide for vulnerable families facing food insecurity in Montreal and across Canada.

The charity is the first winner of the F1 Allwyn Global Community Award 2026 programme. After a successful first year, the Award is shining a global spotlight on even more initiatives - this time recognising up to eight NGOs across the Grand Prix race locations, building on the locations involved last year (Netherlands, Mexico, Austin and Las Vegas).

Later in the season, Formula 1 fans will have the chance to cast their vote on their favourite initiatives, as part of Allwyn's plan to bring these fans closer to the programme. Voters will be able to recognise the impact of the winning initiatives and express their support as they learn more about the NGOs' incredible work and how they're supporting local communities.

Redistributing high-quality, nutritious meals to those in need is a priority for La Tablee des Chefs. It addresses food insecurity in Montreal and across Canada by connecting surplus food donors with local community organisations that distribute meals to individuals and families, and through offering educational programs to promote food autonomy for youth.

The organisation has worked closely with the FORMULA 1 LENOVO GRAND PRIX DU CANADA on food recovery for a number of years. This donation will boost its ability to recover even more food from other large-scale summer events, work with an additional 400 food recovery donors, as well as inspiring other industries to engage in sustainable food recovery practices. Ultimately, the grant will allow La Tablee des Chefs to significantly increase its efforts to feed families in need and rescue millions of meals from being wasted this year.

The judges saw La Tabl?e des Chefs' demonstrable impact and scalability deserving of the winning title, and its mission perfectly aligned to the key pillars of the Award - Sustainability and Innovation, Health and Wellbeing, Education and Opportunity, and Empowerment and Inclusion.

In addition to the EUR100,000 grant, each winner will be presented with a brand new trophy. Designed by Jan Plech?č, creative director of the world-renowned Czech glassworks, Moser, the central element represents Allwyn's stable foundation with the suspended spheres symbolising the successful recipients. Handcrafted and specially created for each winner, the trophy showcases the precision and artistry which define Moser's UNESCO-recognised glassmaking tradition.

Pavel Turek, Chief Officer Global Partnerships, at Allwyn and F1 Allwyn Global Community Award judge, said: "At Allwyn, we believe sport can change the world for the better. Across our markets, we focus on locally-led programmes that deliver meaningful change. So, La Tabl?e des Chefs' dedication to creating real impact, its potential to scale, and its clear alignment to Allwyn's values made it the definitive choice for our F1 Allwyn Global Community Award. We are thrilled to support the charity through the ?100,000 donation, and we look forward to seeing its influence expand internationally and its reach deepen within the Montreal community."

Ellen Jones, Head of ESG at Formula 1 and F1 Allwyn Global Community Award judge, said: "The legacy of La Tabl?e des Chefs and its longstanding relationship with the FORMULA 1 LENOVO GRAND PRIX DU CANADA stood out and truly resonates with the pillars of the Award, along with the incredible work it does for local communities. The charity was able to demonstrate genuine innovation in how it is already creating change and its ambition to grow, a core tenet in our philosophy in how we approach the sport and wider ESG initiatives to deliver meaningful impact."

F1 Allwyn Global Community Award winner, and Founder and CEO of La Tabl?e des Chefs, Jean-Fran?ois Archambault, said: "We are profoundly honoured to be named the winner of the F1 Allwyn Global Community Award. This recognition from Formula 1, coupled with the generous ?100,000 donation from Allwyn, is transformative for La Tabl?e des Chefs, allowing us to significantly expand our work in food recovery and education. Having proudly worked with Formula 1 for a number of years, we are more dedicated than ever to increasing the distribution of high-quality meals to those experiencing food insecurity across Montreal - continuing to redistribute food with dignity while helping organisations reduce food costs and reinvest in support services that help people move out of poverty."

Notes to editors

About Allwyn

Allwyn is a multi-national gaming entertainment company, lottery-led and with leading market positions and trusted brands across Europe and North America, listed on Euronext Athens. Its purpose is to make play better for all by focusing on innovation, technology, player safety and returning more to good causes across a growing casual gaming entertainment portfolio.

About Allwyn's partnership with Formula 1

The multi-year partnership with Formula 1 represents a drive towards increased global awareness for Allwyn, with the sport's 24 races across the globe, 750 million fans, and 96 million social media followers, as well as its reach across broadcast channels and entertainment outlets.

The partnership will reinforce Allwyn's position as an international brand driving community impact across the world, in support of its global growth plans.

At the heart of the partnership is the development of initiatives that will support the company's ambition to be a positive contributor to society globally. With Allwyn and Formula 1 equally committed to empowering fans and local communities, the partnership will give Allwyn the opportunity to utilise the sport's ever-growing international fan base to celebrate those making positive change, sharing these inspiring stories on a global level.

About Formula 1

Formula 1 racing began in 1950 and is the world's most prestigious motor racing competition, as well as the world's most popular annual sporting series. Formula One World Championship Limited is part of Formula 1 and holds the exclusive commercial rights to the FIA Formula One World Championship. Formula 1 is a subsidiary of Liberty Media Corporation (NASDAQ: FWONA, FWONK, LLYVA, LLVYK) attributed to the Formula One Group tracking stock. The F1 logo, F1 Formula 1 logo, Formula 1, F1, FIA FORMULA ONE WORLD CHAMPIONSHIP, GRAND PRIX, PADDOCK CLUB and related marks are trademarks of Formula One Licensing BV, a Formula 1 company. All rights reserved.

Further information about the F1? Allwyn Global Community Award, including eligibility criteria and the selection process, can be found on our website: https://www.allwyn.com/responsibility/community-award.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68d9ff14-ece1-42cd-a3d6-51a601c0a06c

Media enquiries pr@allwyn.com

Press contacts

Formula 1? Press Office

E: f1media@f1.com  

T: @f1media

Copyright 2026 GlobeNewswire, Inc.

Not intended for US and UK media

*New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC)1

*Data for zongertinib monotherapy and in combination in other HER2-altered solid tumors, including breast, colorectal and esophageal cancers, shows encouraging early signals2-4

*Updated data adds to the growing evidence base of obrixtamig in extensive‑stage small cell lung cancer (ES‑SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)5,6

Ingelheim, Germany and Ridgefield, Conn., US - At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Boehringer Ingelheim will present new data from across its robust oncology clinical development program. Key data includes patient-reported outcomes with HERNEXEOS (zongertinib tablets) as an initial orally administered treatment option for HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) and early results evaluating zongertinib in other types of cancer driven by HER2 alterations.1-4 Updated data for obrixtamig, an investigational DLL3/CD3-targeting T-cell engager, will also be presented in extensive-stage small cell lung cancer (ES-SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC).5-6 

"In the past year, Boehringer has meaningfully advanced the NSCLC treatment landscape through multiple regulatory approvals of zongertinib across markets. These new patient-reported outcomes for zongertinib further add to the growing body of evidence characterizing its clinical profile," said Itziar Canamasas, Ph.D., Global Head of Oncology at Boehringer Ingelheim. "Building on this progress, our ambition is to advance precision cancer care across tumor types and modalities by exploring zongertinib's potential in other HER2-driven cancers as well as next-generation approaches such as T-cell engagers. At ASCO, these data reflect our commitment to understanding what truly matters to patients, as we continue to shape an innovative oncology portfolio designed to deliver meaningful, unprecedented impact for people facing cancer." 

Showcasing patient-reported outcomes for zongertinib in HER2-mutant NSCLC

New patient-reported outcomes (N=71) from the Phase Ib Beamion LUNG-1 trial (NCT04886804) showed improvements within one week of treatment in patients' physical functioning with zongertinib as an initial treatment for adult patients with HER2 (ERBB2)-mutant advanced NSCLC, building on the efficacy and safety data that supported the recent U.S. FDA accelerated approval.1 Results showed:

Patients reported improvements in physical functioning and NSCLC‑related symptoms from baseline, which were sustained over time (as measured by EORTC QLQ-C30 and NSCLC-SAQ total score).1

Patient-reported symptomatic adverse events (AEs) as assessed by PRO-CTCAE were in line with zongertinib's published safety data.1

Zongertinib was well tolerated, as reflected by the low overall side effect burden (assessed by EORTC IL46/Q168) and the mild nature for most patient-reported symptomatic AEs (based on PRO-CTCAE measures).1

"For people living with HER2-mutant advanced NSCLC, it's especially important to understand how treatment affects how they feel and function in daily life," said Dr. Joshua K. Sabari, study investigator and Associate Professor, Department of Medicine, New York University (NYU) Grossman School of Medicine; Medical Director, Thoracic Medical Oncology, NYU Langone Health's Perlmutter Cancer Center. "These patient-reported outcomes showed that the patients who received treatment with zongertinib reported improvements in physical functioning and symptom burden. These findings build on previous clinical data to further support the use of zongertinib in the first-line setting for adult patients with HER2-mutant advanced NSCLC." 

Advancing research with zongertinib data in HER2-positive colorectal, esophageal and breast cancers

Early data to be presented highlights the potential of zongertinib in other HER2-driven cancers, including metastatic colorectal cancer (mCRC), metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) and metastatic breast cancer (mBC).2-4 These data will inform continued clinical development across multiple tumor types.

A pooled analysis of patients (N=19) with HER2-positive mCRC from the Phase Ia Beamion LUNG-1 trial (NCT04886804) and the Phase II Beamion PANTUMOR-1 trial (NCT06581432) demonstrated early clinical activity and a manageable safety profile with zongertinib as a monotherapy. The confirmed objective response rate (ORR) was 42% (n=8; all partial responses) and the disease control rate was 95%. The most common treatment-related AEs were diarrhea (n=9), rash (n=3), anemia (n=2), and increased AST (n=2), dysgeusia (n=2) and paronychia (n=2). No grade 4 or 5 AEs were reported.2

Data from Beamion BCGC-1 (NCT06324357), an ongoing Phase Ib/II multicohort trial, showed evidence of clinical activity for zongertinib as a monotherapy and in combination with other agents.3-4

In patients with HER2-positive mGEAC (n=16) who had disease progression following prior trastuzumab-based therapy, confirmed responses with zongertinib in combination with trastuzumab deruxtecan were observed; 10 patients had a confirmed response (1 complete response and 9 partial responses), 5 patients had stable disease responses and 1 patient had progressive disease.3 Zongertinib-related AEs were reported in 85.7% of patients (n=18); the most common treatment-emergent AEs were diarrhea (n=12), nausea (n=10), and anemia (n=5). No grade 4 or 5 AEs were reported and no new safety signals were observed.3

Encouraging clinical activity was observed in heavily pretreated patients with HER2-positive mBC treated with zongertinib in combination with trastuzumab emtansine (Cohort A) and trastuzumab deruxtecan (Cohort B).4 In Cohort A, of the 13 response-evaluable patients, 3 had partial responses and 9 had stable disease. In Cohort B, of the 15 response-evaluable patients, 4 had partial responses and 11 patients had stable disease. No new safety signals were observed with zongertinib in combination with other medicines.4 In Cohort A (n=16), zongertinib-related AEs were reported in 87.5% of patients (n=14); the most common treatment-emergent AEs were increased AST (n=6), increased ALT (n=5), and decreased platelet count (n=5).4 In Cohort B (n=16), zongertinib-related AEs were reported in all patients; the most common treatment-emergent AEs were diarrhea (n=10), nausea (n=10), and anemia (n=7).4

These initial findings highlight the potential of zongertinib beyond lung cancer and support its continued research and development across multiple HER2-driven cancers. 

Exploring DLL3-directed therapy with obrixtamig in ES-SCLC

Updated efficacy and safety results will also be presented from the ongoing Phase I DAREON?‑8 trial with obrixtamig, an investigational DLL3/CD3 T-cell engager, in combination with standard-of-care induction therapy (carboplatin, etoposide and atezolizumab) followed by maintenance obrixtamig plus atezolizumab in the first-line treatment of ES-SCLC (N=44), demonstrating encouraging efficacy. 5

The confirmed ORR was 73%, with 7% of patients achieving a complete response and 66% achieving a partial response, and the disease control rate was 91%. In the 60 mg cohort (n=29), the confirmed ORR was 76% (10% complete response, 66% partial response).5

Median duration of response (mDoR) and median progression‑free survival (PFS) were not yet reached, with 6‑ and 9‑month PFS rates of 78% and 62%, respectively.5

Overall, the safety profile of the combination was generally consistent with the known profiles of the individual agents, with grade ≥3 AEs primarily related to chemotherapy. Cytokine release syndrome was the most common obrixtamig-related AE (57%).5

Discontinuations due to obrixtamig‑related AEs were infrequent (n=1).5

"Given the longstanding need for innovative treatment options in small cell lung cancer, DLL3‑directed approaches such as obrixtamig represent an important area of ongoing research," said Dr. Solange Peters, Professor and Director of Oncology, University Hospital of Lausanne, Switzerland. "In a disease where delivery of later lines of treatment is often not feasible and where urgent disease control is critical, these findings support continued investigation of obrixtamig in combination with standard-of-care therapy as initial treatment of extensive-stage small cell lung cancer." 

Presentations at ASCO 2026 from Boehringer Ingelheim's diverse oncology pipeline reflect its ambition to reshape cancer care: 

About HERNEXEOS (zongertinib tablets) 

HERNEXEOS (zongertinib tablets) is an irreversible tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing wild-type EGFR, thereby minimizing associated toxicities.7,8 HERNEXEOS is approved in the U.S., China, Hong Kong and Japan as the first orally administered targeted therapy for adult patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer. Zongertinib is not approved in other markets. 

The treatment is being evaluated in ongoing trials across a range of earlier stages and advanced solid tumors with HER2 alterations. Beamion LUNG-2 is an ongoing Phase III controlled study evaluating zongertinib as a first-line treatment for patients with advanced NSCLC that have HER2 tyrosine kinase domain mutations (NCT06151574).9 Beamion LUNG-3 is a Phase III clinical trial investigating zongertinib as an adjuvant monotherapy in patients with early-stage, resectable NSCLC (Stage II-IIIB) with HER2 (ERBB2)-mutations (NCT07195695).10

About obrixtamig 

Obrixtamig is an investigational novel Immunoglobin G (IgG)-like bispecific T-cell engager designed to bind concomitantly to DLL3 on tumor cells and CD3 on T-cells, potentially resulting in destruction of tumor cells by the body's own immune system.11 Obrixtamig is being evaluated in multiple, ongoing clinical trials, including a Phase I trial in combination with atezolizumab and chemotherapy in extensive-stage small-cell lung cancer (ES-SCLC) patients (DAREON-8), a Phase Ib study in combination with topotecan in patients with advanced SCLC (DAREON-9), and a Phase II trial in patients with relapsed/refractory DLL3-high extrapulmonary neuroendocrine carcinomas (epNEC) (DAREON-5).5,12,13 Obrixtamig in combination with atezolizumab plus standard of care (SOC) chemotherapy is being evaluated as a first-line treatment vs. atezolizumab plus SOC chemotherapy in a Phase III trial for patients with ES-SCLC (DAREON-LUNG-1).14 Additionally, a Phase III trial is ongoing to evaluate obrixtamig in combination with SOC chemotherapy vs. chemotherapy alone as first-line treatment in patients with DLL3-positive unresectable locally advanced or metastatic epNEC (DAREON-NEC-1).15

About Boehringer Ingelheim in oncology 

We have a clear aspiration - to transform the lives of people facing cancer by delivering unprecedented impact, with the ultimate goal to redefine standards of care. Boehringer Ingelheim's long-term commitment to scientific innovation is reflected by the company's robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as in smart combinations of these approaches. In everything we do, we focus on people - not just data - working alongside them to develop solutions that truly meet their needs and help move cancer into the background of their lives. This drives our research approach, drawing on diverse minds and a long-term perspective to address the needs of people facing cancer today and for generations to come. Read more at https://www.boehringer-ingelheim.com/human-health/cancer.

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. 

References

Sabari, JK, et al. PRO results from the Beamion LUNG-1 trial in treatment-na?ve patients with HER2-mutant advanced NSCLC. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2026; Chicago, IL.

Arnold, D, et al. Zongertinib in HER2-altered colorectal cancer: a pooled analysis of colorectal cancer patients from two clinical trials . Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2026; Chicago, IL.

Nakayama, I, et al. Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC): first results from a Phase Ib/II dose-escalation trial . Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2026; Chicago, IL.

Kitano, S, et al. Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): first results from a phase Ib/II trial. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2026; Chicago, IL.

Peters, S, et al. DAREON?-8: updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC). Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2026; Chicago, IL.

Gambardella, V.  et al. Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial. Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29 - June 2, 2026; Chicago, IL.

HERNEXEOS Prescribing Information.

Wilding B, Woelflingseder L, Baum A, et al. Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov. 2025;15(1):119-138. doi:10.1158/2159-8290.CD-24-0306

ClinicalTrials.gov. Beamion LUNG-2 (NCT06151574). Accessed May 2026.

ClinicalTrials.gov. Beamion LUNG-3 (NCT07195695). Accessed May 2026.

Wermke M, Gambardella V, Kuboki Y, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol. 2025;43(27):3021-3031.

ClinicalTrials.gov. DAREON-9 (NCT05990738). Accessed May 2026.

ClinicalTrials.gov. DAREON-5 (NCT05882058). Accessed May 2026.

ClinicalTrials.gov. DAREON-Lung-1 (NCT07472517). Accessed May 2026.

ClinicalTrials.gov. DAREON-NEC-1 (NCT07544654). Accessed May 2026.

Copyright 2026 GlobeNewswire, Inc.

KUALA LUMPUR, Malaysia, May 21, 2026 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) ("VCI Global" or the "Company") today announced that it received a notification letter from the Nasdaq Stock Market LLC ("NASDAQ") on May 19, 2026 regarding the delayed filing of the Company's Form 20-F for the financial year ended December 31, 2025.

The notice relates to the timing of the Company's filing of its Form 20-F under NASDAQ Listing Rule 5250(c)(1), which requires listed companies to periodically file financial reports with the U.S. Securities and Exchange Commission ("SEC").

As previously disclosed, the Company filed a Form 12b-25 (Notification of Late Filing) with the SEC on May 1, 2026, after requiring additional time to complete the preparation and final review of its financial statements and related disclosures for the 2025 Form 20-F.

VCI Global is actively working toward completing the filing and has begun the process of submitting a compliance plan to NASDAQ. Subject to NASDAQ's review and acceptance of the plan, the Company may be granted additional time of up to 180 calendar days from the original filing deadline to regain compliance.

The notice has no immediate effect on the listing or trading of the Company's ordinary shares on NASDAQ, and trading will continue as normal during this process.

The Company remains committed to maintaining strong reporting standards and keeping shareholders informed on further developments.

About VCI Global Limited

VCI Global Limited (NASDAQ: VCIG) is an AI-native operating platform designed to scale and optimize businesses through centralized intelligence, data, and capital discipline.

The Company operates a platform-based model in which subsidiaries, affiliates, and portfolio companies plug into VCI Global's centralized AI, data, governance, and capital allocation systems, enabling faster execution, improved capital efficiency, and scalable growth across multiple industries.

VCI Global's platform centralizes AI-enabled execution, standardized KPI frameworks, financial and governance controls, and strategic capital allocation, while operating businesses focus on revenue generation, customer relationships, and local execution.

The Company maintains exposure across advisory, AI, and digital infrastructure, digital assets, energy, automotive, and consumer sectors, and continuously evaluates opportunities to scale, spin off, divest, or discontinue businesses based on performance, scalability, and return on capital.

VCI Global's platform-centric approach is designed to enhance productivity, improve IPO readiness, and unlock long-term value through disciplined growth and selective capital deployment.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. These forward-looking statements are based only on our current beliefs, expectations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company's ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company's products and the Company's customers' economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company's filings with the United States Securities and Exchange Commission ("SEC"). The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

For media queries, please contact:

VCI GLOBAL LIMITED

enquiries@v-capital.co

Copyright 2026 GlobeNewswire, Inc.

BANGKOK, THAILAND - Media OutReach Newswire - 22 May 2026 - Charoen Pokphand Foods Public Company Limited (CPF), a leading global agro-industrial and food company, is positioning Thailand as a regional food innovation hub at THAIFEX - Anuga Asia 2026, showcasing its latest food innovations developed for global consumers.

The showcase highlights how Thai expertise, advanced production capabilities, consumer-centric R&D, and robust strategic partnerships are delivering high-quality, sustainable food experiences to consumers worldwide.

Under the concept "Food Innovation for Wellness," CPF is showcasing a diverse portfolio of market-driven food innovations developed to meet the evolving needs of consumers across Europe, North America, the Middle East, and Asia. The showcase highlights the company's commitment to food safety, quality, wellness, and convenience, including products inspired by its experience in developing Thai-style chicken with basil sauce to meet stringent space-grade food safety standards, as well as the newly launched CP Nippon brand.

Prasit Boondoungprasert, Chief Executive Officer of CPF, said "Consumers around the world are looking for food that is not only safe and delicious, but also convenient, nutritious, and responsibly produced. At CPF, we believe food plays an important role in people's everyday lives. We are committed to understanding consumers and business partners in every market and continuously developing innovative food solutions that deliver better experiences, support wellbeing, and meet the evolving needs of consumers worldwide."

At this year's exhibition, CPF highlights its strengths as a global food company with international operations with local market insight, powered by innovation and technology to serve partners and consumers worldwide while helping advance more sustainable food systems.

The showcase features a diverse portfolio of ready-to-eat meals, premium protein products, convenience foods, and international award-winning menu innovations from CPF's global brand portfolio, including Authentic Asia, CP Uoriki, CP Nippon, and Thai Cube. All are designed to meet growing consumer demand for safer, healthier, tastier, more convenient, and tailored to changing consumer lifestyles.

At THAIFEX ? ANUGA ASIA 2026, CPF welcomes business partners, customers, and visitors from around the world to explore its latest global food innovations at booths 1-RR01 and 1-RR15 in Challenger Hall 1.

About CPF

Charoen Pokphand Foods Plc (CPF) is a leading global agro-industrial and food company, operating in 17 countries and exporting to more than 50 markets worldwide. Guided by its "Kitchen of the World" vision, CPF focuses on delivering safe, high-quality, and nutritious food through a vertically integrated business model. The company integrates technology and innovation across its operations while advancing sustainability and working toward a low-carbon, resilient food system that supports global food security.

The issuer is solely responsible for the content of this announcement.

Hashtags: #THAIFEXAnugaAsia #FoodInnovation #FoodTech #FutureOfFood #SustainableFood #FoodSafety #CPFXTHAIFEX2026 #FoodInnovationForWellness #THAIFEX2026

SAN FRANCISCO, CALIFORNIA, UNITED STATES - Media OutReach Newswire - 22 May 2026 - Via Licensing Alliance (Via) today announced continued momentum for its Voice Codec patent pool, including the addition of a new unnamed licensee and new licensors, NovaVoice Limited and Cordial IP, further growing the program's patent stack and market penetration from its initial five, large global licensors.

The addition of the new licensee, unnamed at this time, reflects growing industry adoption of the collaborative licensing pathway Via's Voice Codec program creates for accessing IP rights to critical voice technologies. This addition reflects a growing market uptake of advanced voice technologies, including EVS and IVAS, driven by rising demand as 5G and 5G-Advanced technologies are adopted worldwide.

Additionally, Via continues to prioritize transparency and has published its full rate structure for the Voice Codec pool, providing further clarity and predictability for implementers and to the broader market. For implementers, the full rate structure allows for complete visibility as they consider the appropriate royalty structure to choose from to meet their product level costs, evaluate future growth paths for their product lines, or plan their geographical expansion plan needs. This level of disclosure not only reduces uncertainty in licensing decisions but also enables more consistent benchmarking, reinforcing confidence in fair, market-aligned SEP licensing practices. The program's royalty rates are listed on Via's website at https://www.via-la.com/licensing-programs/voice-codec/#license-fees.

The addition of the new licensors indicates increased interest from patent holders in licensing their voice technology SEPs through highly efficient, aggregated licensing vehicles such as patent pools. Future growth in both the licensor list and the number of patents consolidated through the pool license will continue to enhance the value of the Voice Codec License for implementers. Via's Voice Codec program licensors are listed here: https://www.via-la.com/licensing-programs/voice-codec/#licensors.

Via's Voice Codec pool covers Enhanced Voice Services (EVS), which supports voice communications across more than one billion and growing active devices globally, as well as Immersive Voice and Audio Services (IVAS), which will play a central role in next-generation voice and spatial audio applications.

"We are pleased to welcome these new entrants to our pool, which signal continued growth and momentum our Voice Codec program," said Kevin Mack, President of Via Licensing Alliance. "This pool license offers strong value relative to other market options and represents the only collaborative licensing solution for EVS and IVAS technologies, making it a smart and efficient pathway for companies seeking to license critical voice capabilities."

EVS remains a foundational technology for high-quality voice communications in 5G and 5G-Advanced networks, with adoption continuing to expand as 5G, 5G-Advanced and future network iterations reach global scale. As spatial audio and advanced voice technologies expand into 6G and a broader range of non-cellular devices, the importance of IVAS technologies is expected to increase, with Via's pool offering an early and effective licensing pathway.

About Via Licensing Alliance:

Via Licensing Alliance is the collaborative licensing leader, dedicated to accelerating global technology adoption, fostering participation, and generating return on innovation with balanced licensing solutions for innovators and manufacturers of all sizes around the globe. Via has operated dozens of licensing programs for a variety of technologies. Via is an independently managed company owned by industry-leading participants with over 25 years of intellectual property licensing leadership. For more information about Via, please visit https://www.via-la.com.

The issuer is solely responsible for the content of this announcement.

Hashtags: #ViaLicensingAlliance #VIA

SAN FRANCISCO, USA - Media OutReach Newswire - 21 May 2026 - From May 11 to 14, a Hainan economic and trade delegation, jointly organized by the China Council for the Promotion of International Trade Hainan Provincial Committee (CCPIT Hainan)and the Hainan Youth Federation, visited the United States to conduct business exchange activities aimed at accelerating bilateral trade and investment between Hainan and the U.S. The delegation, comprising over 20 members, included heads of enterprises and institutions from sectors such as international trade, port logistics, digital technology, marine environmental protection, legal services, and modern agriculture.

At the China (Hainan Free Trade Port)?U.S. (San Francisco) Economic and Trade Exchange Meeting, the delegation highlighted the policy advantages and innovative achievements of the Hainan Free Trade Port to American enterprises. The two sides engaged in extensive exchanges in areas such as international trade, modern services, high-tech industries, and cross-border investment.

The head of the delegation noted that since the Hainan Free Trade Port began island-wide special customs operations on December 18, 2025, policy dividends have been steadily unleashed. The customs supervision model of "freer access at the first line, regulated access at the second line" has been fully implemented. The number of zero-tariff commodity items has been expanded to 6,631. Additionally, the policy of exempting tariffs on processed goods with a value-added rate exceeding 30% has created new cost advantages for cooperation between Chinese and U.S. enterprises.

Sean Randolph, a representative of the Bay Area Council, stated that direct exchanges between companies are essential for establishing long-term cooperative relationships. He noted that the San Francisco Bay Area, as a key gateway for Pacific trade, has maintained long-standing economic ties with Asia, particularly China. As the Hainan Free Trade Port continues to develop, sectors such as services, life sciences, and tourism are creating new opportunities for collaboration with California-based businesses.

During the visit, the delegation also participated in the 2026 China-California Economic and Trade Forum and held business negotiations with U.S. companies. The CCPIT Hainan signed a memorandum of cooperation with the Sino America Business Information Center to support the establishment of a platform for bilateral economic and trade cooperation and exchanges.

In addition, the delegation visited institutions such as the American-Chinese CEO Society, the Huamei Business Information Center, the Silicon Valley Open Intelligent Culture Foundation, and Sidley Austin LLP, engaging in in-depth exchanges on cross-border investment , specialized industry development, and commercial legal matters.

In June 2020, China unveiled a master plan to build the whole of Hainan Island into a globally influential and high-level free trade port by the middle of the century. The initiative reached a major milestone in December last year with the launch of island-wide special customs operations, which marked the completion of the first key step toward that goal.

The move has turned the island into a special customs supervision zone, allowing freer trade between Hainan and areas outside China's customs borders, while enforcing standard customs controls for goods moving from Hainan to the mainland.

The issuer is solely responsible for the content of this announcement.

Hashtags: #CPITHainan

ROCHESTER, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, today announced the election of Morgan Flatley of McDonald's Corporation (NYSE: MCD), the world's leading global foodservice retailer, to serve as a member of its Board of Directors effective May 20, 2026.

"We're excited to welcome Morgan to Constellation Brands' Board of Directors," said Constellation Brands Board Chair Chris Baldwin. "Morgan's extensive global brand-building experience in both the consumer-packaged goods and food and beverage sectors will benefit Constellation as we continue to position the company to remain the #1 high-end beer supplier in the U.S. by dollar sales and a leader in dollar share gains within the dynamic beverage alcohol category."

Flatley currently serves as Executive Vice President, Global Chief Marketing Officer and New Business Ventures at McDonald's Corporation, where she is responsible for global brand building, including driving the company's growth and transformation across marketing, menu, value platforms, digital customer engagement, insights, and new business ventures.

Since joining McDonald's in 2017, Flatley has been the driving force behind some of the Brand's most inspired marketing campaigns. She has been named to the Forbes World's Most Influential CMOs list multiple times and has been recognized with Adweek's most prestigious honor ? Brand Genius. Under Flatley's leadership, McDonald's has also been recognized multiple times as a top marketer among consumer brands.

Prior to joining McDonald's, Flatley spent 13 years at PepsiCo, Inc., a multinational food, snack, and beverage company, most recently serving as Senior Vice President and Chief Marketing Officer, Global Nutrition, responsible for brand positioning and innovation for Quaker, Tropicana, Gatorade, and Naked Juice.

"Constellation Brands has built one of the most distinctive and iconic brand portfolios in the industry by staying deeply attuned to consumers and shaping culture, not just responding to it," said Flatley. "I look forward to collaborating with my fellow board members and lending perspective to help Constellation's executive team continue building on the company's strong foundation for growth and track record of success."

With Flatley's election, the composition of Constellation Brands' Board of Directors returns to twelve members, following former President and Chief Executive Officer Bill Newlands' retirement from the Board in April 2026. Flatley's election serves as a continuation of the company's comprehensive board refreshment process.

ABOUT CONSTELLATION BRANDS

Constellation Brands (NYSE: STZ) is a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. It's worth our dedication, hard work, and calculated risks to anticipate market trends and deliver for our consumers, shareholders, employees, and industry. This dedication is what has driven us to become one of the fastest-growing, large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what's next.

Every day, people reach for brands from our high-end, imported beer portfolio anchored by the iconic Corona Extra and Modelo Especial, a flavorful lineup of Modelo Cheladas, and favorites like Pacifico, and Victoria; our exceptional wine brands including The Prisoner Wine Company, Robert Mondavi Winery, Kim Crawford, Schrader Cellars, and Lingua Franca; and our craft spirits brands such as Casa Noble Tequila and High West Whiskey.

As an agriculture-based company, we strive to operate in a way that is sustainable and responsible. Our ESG strategy is embedded into our business and we focus on serving as good stewards of the environment, investing in our communities, and promoting responsible beverage alcohol consumption. We believe these aspirations in support of our longer-term business strategy allow us to contribute to a future that is truly Worth Reaching For.

To learn more, visit www.cbrands.com and follow us on LinkedIn and Instagram.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements. The word "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements may relate to business strategy, future operations, prospects, plans, and objectives of management and Constellation's Board of Directors, including the anticipated benefits of Flatley's experience, positioning of the company as a high-end beer supplier and beverage alcohol category leader, and building on the company's strong foundation for growth and track record of success, as well as information concerning expected actions of third parties. All forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those set forth in, or implied by, such forward-looking statements.

The forward-looking statements are based on management's and the Constellation Board of Directors' current expectations and should not be construed in any manner as a guarantee that any of the events anticipated by the forward-looking statements will in fact occur or will occur on the timetable contemplated hereby. All forward-looking statements speak only as of the date of this news release and Constellation does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

In addition to risks and uncertainties associated with ordinary business operations, the forward-looking statements contained in this news release are subject to other risks and uncertainties, including the accuracy of all projections and other factors and uncertainties disclosed from time-to-time in Constellation Brands' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended February 28, 2026, which could cause actual future performance to differ from current expectations.

MEDIA CONTACTS INVESTOR RELATIONS CONTACTS

Maggie Bowman 213-500-2401 / Blair Veenema 585-284-4433 /

maggie.bowman@cbrands.com blair.veenema@cbrands.com 

  Snehal Shah 847-385-4940 /

  snehal.shah@cbrands.com

  David Paccapaniccia 585-282-7227 /

  david.paccapaniccia@cbrands.com

   

A downloadable PDF copy of this news release can be found here. http://ml.globenewswire.com/Resource/Download/1aea2f9c-8253-45d2-8d94-2b14f1703079

Copyright 2026 GlobeNewswire, Inc.

Boehlert's proven capital markets expertise further strengthens the company's Board leadership as it advances towards the public markets

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- General Fusion Inc. ("General Fusion" or the "Company"), a leader in the global race to commercialize fusion energy, today announced that Thomas Boehlert was appointed to the Company's Board of Directors, effective May 12, 2026.

In addition to his role as a director, Boehlert was appointed to serve as Chair of the Nominating and Governance Committee as the Company prepares to go public through its previously announced business combination (the transactions contemplated by the business combination, collectively, the "Proposed Business Combination") with Spring Valley Acquisition Corp. III (NASDAQ: SVAC) ("SVAC").

Boehlert brings over three decades of experience across industrials, natural resources, agribusiness, power generation, and the energy transition. Most recently, he served as Chief Financial Officer at US Strategic Metals and as a director of Arizona Sonoran Copper Company.

"I'm pleased to join General Fusion at such an important stage in its growth, particularly as it aligns with my interest in companies helping to drive the global energy transition," said Thomas Boehlert. "Having worked with companies at similar inflection points, I look forward to aligning technical progress with disciplined execution as the business moves from development to deployment."

"Thomas brings an excellent combination of deep capital markets expertise and hands-on leadership experience to our Board of Directors," said Greg Twinney, Chief Executive Officer of General Fusion. "His guidance will be invaluable as General Fusion advances our transformational technology toward commercialization, strengthening the governance, controls, and strategic discipline needed for our transition to a public company."

Boehlert has held a suite of leadership roles throughout his career, including CFO of Bunge Limited, CFO of Kinross Gold, and CEO of First Nickel, among earlier CFO roles in the power sector.

"We are very pleased to welcome Thomas to the Board at such a pivotal point in the company's evolution," said Klaas de Boer, Chair, General Fusion Board of Directors. "His counsel will be invaluable as we position the business for long-term, scalable success. We look forward to working closely with him and benefiting from his judgment, discipline, and experience as we navigate the opportunities and responsibilities that come with being a public company."

About Thomas Boehlert

Boehlert is an experienced public company executive and director, having served as both CEO and CFO across the industrial, natural resources, agribusiness, power, and energy sectors. He has held senior roles including CFO of US Strategic Metals, EVP & CFO of Bunge Limited, CFO of Kinross Gold, and CEO of First Nickel, as well as earlier CFO positions in the power sector.

Across his executive career, Boehlert has led portfolio reshaping, capital structure optimization, and operational improvements through periods of market volatility and strategic change.

He also brings significant board experience, serving as Audit Committee Chair, Compensation Committee Chair, and a Special Committee member for public companies, with a focus on governance, capital allocation, and major transactions, including IPOs and strategic reviews.

Quick Facts:  

General Fusion's Magnetized Target Fusion ("MTF") is designed to solve significant barriers to commercializing fusion energy at a time when electricity demand is surging, and nations around the world are racing to commercialize fusion power.  

As a technology, MTF aims to achieve fusion in a practical way, avoiding superconducting magnets and high-powered lasers, while enabling the use of existing materials for durable machines that would produce cost-effective energy. 

In early 2025, General Fusion announced that it had designed, built, and begun operating its world-first Lawson Machine 26 ("LM26") fusion demonstration machine in under two years. LM26 is the first MTF demonstration machine to be built at a commercially relevant scale. It mechanically compresses plasma with a lithium liner at 50% commercial-scale diameter.  

LM26 aims to achieve key fusion technical milestones: plasma heating to 1 keV (10 million degrees Celsius), then 10 keV (100 million degrees Celsius), and ultimately the Lawson criterion, the combination of fusion parameters that can produce net fusion energy in the plasma. 

About General Fusion

General Fusion is pursuing a fast and practical approach to commercial fusion energy and is headquartered in Vancouver, Canada. The Company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com. General Fusion announced in January 2026 that it plans to go public through the Proposed Business Combination with Spring Valley Acquisition Corp. III (NASDAQ: SVAC).

About Spring Valley Acquisition Corp. III

Spring Valley Acquisition Corp. III is a part of a family of investment vehicles formed for the purpose of acquiring or merging with a business focused on the Power infrastructure and Decarbonization sectors. Over the past 5 years, Spring Valley has raised $920 million in four IPOs. Spring Valley I successfully completed its business combination with NuScale Power, a leading U.S. small modular reactor ("SMR") technology company, and Spring Valley II successfully completed its business combination with Eagle Nuclear Energy Corp., a next-generation nuclear energy company with rights to the largest open pit-constrained measured and indicated uranium deposit in the United States. SVAC maintains a corporate website at https://sv-ac.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements included in this document are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document are forward-looking statements. Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. In some cases, you can identify forward-looking statements by words such as "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "strategy," "future," "opportunity," "may," "target," "should," "will," "would," "will be," "will continue," "will likely result," "preliminary," or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include, without limitation, SVAC's, General Fusion's, or their respective management teams' expectations concerning the Proposed Business Combination and expected benefits or timing thereof; the outlook for General Fusion's business, including its ability to commercialize MTF or any other fusion technology on its expected timeline or at all; statements regarding the current and expected results of General Fusion's LM26 program; the ability to execute General Fusion's strategies, including on any expected timeline or anticipated cost basis; projected and estimated financial performance; anticipated industry trends; future capital expenditures; government regulation of fusion energy; and environmental risks; as well as any information concerning possible or assumed future results of operations of General Fusion. The forward-looking statements are based on the current expectations of the respective management teams of SVAC and General Fusion, as applicable, and are inherently subject to uncertainties and changes in circumstance and their potential effects. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, (i) the risk that the Proposed Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of SVAC's securities; (ii) the failure to satisfy the conditions to the consummation of the Proposed Business Combination, including the adoption of the business combination agreement, dated January 21, 2026, among General Fusion, SVAC, and the other party thereto (the "Business Combination Agreement") by the shareholders of SVAC and the receipt of regulatory approvals; (iii) market risks; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement; (v) the effect of the announcement or pendency of the Proposed Business Combination on General Fusion's business relationships, performance, and business generally; (vi) risks that the Proposed Business Combination disrupts current plans of General Fusion and potential difficulties in its employee retention as a result of the Proposed Business Combination; (vii) the outcome of any legal proceedings that may be instituted against General Fusion or SVAC related to the Business Combination Agreement or the Proposed Business Combination; (viii) failure to realize the anticipated benefits of the Proposed Business Combination; (ix) the inability to maintain the listing of SVAC's securities or to meet listing requirements and maintain the listing of the combined company's securities on Nasdaq; (x) the risk that the Proposed Business Combination may not be completed by SVAC's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by SVAC; (xi) the risk that the price of the combined company's securities may be volatile due to a variety of factors, including changes in laws, regulations, technologies, natural disasters, national security tensions, and macro-economic and social environments affecting its business; (xii) laws and regulations governing General Fusion's research and development activities, and changes in such laws and regulations; (xiii) any failure to commercialize MTF on the expected timeline or at all, including any failure to achieve the objectives of the LM26 program; (xiv) environmental regulations and legislation; (xv) the effects of climate change, extreme weather events, water scarcity, and seismic events, and the effectiveness of strategies to deal with these issues; (xvi) fluctuations in currency markets; (xvii) General Fusion's ability to complete and successfully integrate any future acquisitions; (xviii) increased competition in the fusion industry; (xix) limited supply of materials and supply chain disruptions; and (xx) the risk that the proposed private placement of convertible preferred shares and warrants by General Fusion (the "PIPE Financing") may not be completed, or that other capital needed by the combined company may not be raised on favorable terms, or at all, including as a result of the restrictions agreed to in connection with the PIPE Financing. The foregoing list is not exhaustive, and there may be additional risks that neither SVAC nor General Fusion presently know or that SVAC and General Fusion currently believe are immaterial. You should carefully consider the foregoing factors, any other factors discussed in this document and the other risks and uncertainties described in the "Risk Factors" section of SVAC's final prospectus for its initial public offering, which was filed with the SEC on September 4, 2025 (the "Final Prospectus"); the risks described in the joint registration statement on Form F-4 filed by General Fusion and SVAC, as amended (the "Registration Statement"), which includes a preliminary proxy statement/prospectus, or to be described in any amendment or supplement thereto; and those discussed and identified in filings made with the SEC by SVAC from time to time. General Fusion and SVAC caution you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth in this document speak only as of the date of this document. Neither General Fusion nor SVAC undertakes any obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs. In the event that any forward-looking statement is updated, no inference should be made that General Fusion or SVAC will make additional updates with respect to that statement, related matters, or any other forward-looking statements. Any corrections or revisions and other important assumptions and factors that could cause actual results to differ materially from forward-looking statements, including discussions of significant risk factors, may appear, up to the consummation of the Proposed Business Combination, in SVAC's public filings with the SEC, which are or will be (as applicable) accessible at www.sec.gov, and which you are advised to review carefully.

Important Information for Investors and Shareholders

In connection with the Proposed Business Combination, General Fusion and SVAC filed with the SEC the Registration Statement, which includes a preliminary prospectus with respect to SVAC's securities to be issued in connection with the Proposed Business Combination and a preliminary proxy statement in connection with SVAC's solicitation of proxies for the vote by SVAC's shareholders with respect to the Proposed Business Combination and other matters described in the Registration Statement (the "Proxy Statement"). After the SEC declares the Registration Statement effective, SVAC plans to file the definitive Proxy Statement with the SEC and to mail copies to SVAC's shareholders as of a record date to be established for voting on the Proposed Business Combination. This document does not contain all the information that should be considered concerning the Proposed Business Combination and is not a substitute for the Registration Statement, Proxy Statement or for any other document that SVAC has filed or may file with the SEC. Before making any investment or voting decision, investors and security holders of SVAC and General Fusion are urged to read the Registration Statement and the Proxy Statement, and any amendments or supplements thereto, as well as all other relevant materials filed or that will be filed with the SEC in connection with the Proposed Business Combination as they become available because they will contain important information about General Fusion, SVAC and the Proposed Business Combination. Investors and security holders are able to obtain free copies of the Registration Statement, the Proxy Statement and all other relevant documents filed or that will be filed with the SEC by SVAC through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by SVAC may be obtained free of charge from SVAC's website at https://sv-ac.com or by directing a request to Spring Valley Acquisition Corp. III, Attn: Corporate Secretary, 2100 McKinney Avenue, Suite 1675, Dallas, Texas 75201. The information contained on, or that may be accessed through, the websites referenced in this document is not incorporated by reference into, and is not a part of, this document. 

Participants in the Solicitation

General Fusion, SVAC and their respective directors, executive officers and other members of management and employees may, under the rules of the SEC, be deemed to be participants in the solicitations of proxies from SVAC's shareholders in connection with the Proposed Business Combination. For more information about the names, affiliations and interests of SVAC's directors and executive officers, please refer to the Final Prospectus and the Registration Statement, Proxy Statement and other relevant materials filed or to be filed with the SEC in connection with the Proposed Business Combination when they become available. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, which may, in some cases, be different than those of SVAC's shareholders generally, will be included in the Registration Statement and the Proxy Statement, when they become available. Shareholders, potential investors and other interested persons should read the Registration Statement and the Proxy Statement carefully, when they become available, before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. 

No Offer or Solicitation

This document shall not constitute a "solicitation" as defined in Section 14 of the Securities Exchange Act of 1934, as amended. This document shall not constitute an offer to sell or exchange, the solicitation of an offer to buy or a recommendation to purchase, any securities, or a solicitation of any vote, consent or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. No offering of securities in the Proposed Business Combination shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. 

Investor Relations Contact:

You can contact General Fusion's Investor Relations team by email at: investors@generalfusion.com.

If you are based in North America, you may also leave a toll-free voicemail at +1 (833) 717-1519. Callers outside North America can reach us at +1 (236) 253-6968. 

Media Relations Contact:

media@generalfusion.com 

1-866-904-0995 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a28f1739-eb2f-4799-865c-bf1b77ca2d4f

Copyright 2026 GlobeNewswire, Inc.

The number of small to mid-sized businesses joining Cority jumped 119% year-over-year in 2025 as companies aim to consolidate on AI-enabled EHS+ platforms

TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Cority, the converged platform for preventing EHS+ risks in operations, today announced new evidence of an accelerating market shift: an increasing share of companies with leaner operations are leaving fragmented and homebuilt EHS+ tools behind in favor of converged, AI-ready platforms.

Cority saw a 119% year-over-year growth in new small and medium-sized business customers in 2025. For the last two decades, modern EHS+ platforms have primarily been adopted by the largest enterprises. This data signals the market is undergoing a massive shift.

Cleaveland/Price, a 380-person Pennsylvania-based manufacturer of high-voltage electrical switchgear for the electric utility industry, is one of those customers. The company spent years managing EHS on paper, eventually moved to a basic system as it grew, and quickly hit its ceiling. Today, Cleaveland/Price runs incident management and EHS observation on Cority, is preparing to roll out risk management, and is evaluating Cortex AI agents as the next step - a modernization arc Cority's data shows is now repeating across the segment.

"When we started with Cority, we needed a system to help take our EHS processes to the next level. We had moved from paper forms to a basic system, but needed something we could truly grow into," said Nick Braun, EHS Manager at Cleaveland/Price.

"We began with the incident module and included our EHS Observation Program, and the difference was immediate - we went from free-text chaos to real, trendable data almost overnight, which is now used proactively across our communication tools and systems. Now we're preparing to roll out risk management, and we know Cortex AI is on the horizon. That's the beauty of it - we didn't have to implement everything at once; we were able to set our own pace to ensure the process was effective."

For most of the last two decades, modern EHS+ platforms were the domain of the largest enterprises - global manufacturers, energy companies, and chemical operators with dedicated EHS teams and complex multi-site compliance footprints. Smaller and leaner operators have historically relied on a mix of spreadsheets, paper, and single-purpose point tools to keep up. AI is changing that.. Predictive risk insights, agentic workflows, and automated compliance - capabilities that once required enterprise-scale data infrastructure - are now the baseline expectation across the market. But smaller, leaner companies are finding that those tools can't be retrofitted to deliver them. New research from Cority's State of EHS+ Technology 2026 report confirms the pace: 62% of EHS+ leaders now say the need to apply AI is pushing them toward integrated platforms and IT consolidation, and 88% report that fragmented data and disconnected systems are limiting their teams' ability to use AI.

"We've been calling EHS+ an inflection-point industry for a while, and what's striking now is how clearly that shift shows up among companies with leaner operations," said Ryan Magee, CEO of Cority. "They've watched what fragmented EHS+ technology costs their larger peers, and they're done waiting for AI to be retrofitted onto tools that weren't built for it. They want the same modern foundation, sized to how they actually operate."

"What's changed most is who's at the table. We're sitting across from EHS leaders at 400-person manufacturers and 1,500-person energy and chemical operators who five years ago wouldn't have engaged with a platform like Cority. They were patching together point tools and figuring it out themselves. Now they're walking in saying they want what their larger competitors have - and increasingly, they're saying they want the AI piece, not as a future state but as a starting point, " said Emily Crawford, CRO at Cority.

These customers most often start with Cority's core packages - Safety Core, Safety Essentials, Environmental Compliance Core, or Sustainability. Each is built on the same converged platform architecture and embedded Cortex AI agents that anchor Cority's enterprise deployments, sized to how leaner operations actually run.

Where the growth is coming from

The strongest uptake is coming from the same industries that have long defined Cority's business - manufacturing, mining and metals, energy, oil and gas, chemicals, and construction - now navigating the most significant operational reset in decades. Tariffs, supply chain reshuffling, the AI infrastructure build-out, and the global push to electrify and decarbonize are forcing these companies to stand up new facilities, new workforces, and new compliance programs faster than legacy EHS systems were built to support.

These are also the companies where the cost of getting EHS+ wrong has always been highest. As change accelerates, more of them are choosing modern, AI-ready platforms over patching together point tools.

What's next

Cority will continue this conversation at ASSP Safety 2026 in Anaheim, California next month, demonstrating live how a safety program at a 500-person manufacturer can stand up the same AI-enabled, converged platform that runs at a 50,000-person global enterprise - and what changes when it does.

Cority's findings reinforce a pattern the company has been documenting across its market for more than a year: as AI reshapes EHS+, companies of every size are converging on modern, agent-enabled platforms.

About Cority

Cority helps customers see and prevent risks across their operations in real time. Our EHS+ platform converges people, processes, data, and AI agents to provide a clear view of information people can trust, automate workflows that make people more impactful, and deliver personalized insights and expertise to improve decision-making. Cortex AI puts domain-expert intelligence directly into everyday workflows - secure by design, governed by you, and built to scale. While most solutions respond to risks one at a time, Cority helps prevent them across environmental management, employee health, safety, quality, and sustainability. For 40 years, Cority has been the market leader in EHS+, recognized by top analysts and trusted by more than 1,500 of the most complex organizations worldwide. Learn more at cority.com.

Media Contact: Natalie Rizk natalier@theriotmind.agency

Copyright 2026 GlobeNewswire, Inc.

The latest version of Computer, by DevRev, delivers speed with clarity, including expanded shared memory for individuals, teams, and organizations; a new content-producing desktop app; Agent Studio for AI agent development; and multiplayer AI

PALO ALTO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- DevRev, an AI-native enterprise software company transforming how teams and customers collaborate, today announced the newest release of Computer, by DevRev, its AI teammate for enterprise teams. The release addresses the three biggest failures of modern enterprise AI: models that have no memory of a business, insights that disappear the moment they leave a user's screen, and AI that answers questions but can't safely take action.

The rest of the industry has responded to these failures by focusing on selling speed - working faster, producing more outputs, increasing token use - resulting in organizations running world-class models on ineffective infrastructure. The Upwork Research Institute states that 96% of C-suite leaders expect AI to boost worker productivity, but 77% of employees report AI has increased their workload. Focusing on metrics like speed and token volume - "token maxxing" - without clarity distracts from progress, and advocating for applying more compute to inadequate contextual data only produces more noise.The result: knowledge workers lose hours a day hunting for information across disconnected systems, and the people meant to benefit from AI are left holding the bill for its failures.

Computer is built on a different philosophy: delivering both speed and clarity. This solves the context problem through "shared memory," a curated, living picture of an organization's data, how the organization works, and how its people interact. Shared memory is the architectural foundation that enables:

Precision: answers sourced from real business data, cited and referenced so teams can stand behind them.

Efficiency: trusted answers at lower cost, lower token usage, no analyst required, full context on the first response.

Safety: nothing goes out before a human approves it, with full audit trails and the ability to undo any agent action.

When AI has this context, it stops guessing and starts acting like a trusted member of the team. Reliable performance builds trust; trust unlocks action. That progression - from trusted answers to safe actions - is what makes multiplayer collaboration between humans and AI possible across every function.

"Every AI company is selling speed, which is fueling the next enterprise crisis. This will be the latest form of workplace burnout if we don't do something about it," said Dheeraj Pandey, Co-founder and CEO at DevRev. "Speed without the right context is just faster noise, noise that overloads humans in the loop, and eventually breaks them. Computer is built on a different philosophy: work softer. Give AI the enterprise memory and shared context it needs to perform reliably, and then let it take action. Only then will your people have the confidence that the AI they use is performing the tasks they need it to, more accurately and with less handholding."

What is new in the newest release of Computer

The evolution of shared memory at every level ensures that every Computer session now builds on the last. At the individual level, Computer learns how each person works, picking up where they left off with each new session. At the team level, the skills and AI agents one person develops become available to everyone. At the organizational level, institutional knowledge stays in the system permanently. When a top-performing rep leaves, their account knowledge does not leave with them.

Before this release, AI insight disappeared the moment it left one person's screen. Now the introduction of Multiplayer AI lets teams share a live Computer session where everyone sees the full context and continues the analysis together. Colleagues can question, build on, and correct reasoning in real time. In a 2025 study, KPMG and University of Melbourne reported that 57% of employees admit to using AI in non-transparent ways, including avoiding revealing when they have used AI tools to complete their work. Teams rarely benefit from one another's AI work. Multiplayer AI changes the unit of attribution from "what I did with AI" to "what we did with AI, together."

Earlier versions of Computer answered questions and took single-step actions. The addition of the new desktop app shifts Computer from a question-answering tool to a content-producing system. From the in-app canvas, any user can generate complete, fully branded and formatted work artifacts grounded in real business data: competitive slide decks, QBR reports, structured dashboards, knowledge base articles, and multi-step workflows; these outputs are available in a variety of file formats, including PPT, HTML PDF, DOCX, and more. Skills and outputs built in the Canvas are saved at the user, team, or organization level and become reusable across the business.

Agent Studio gives any team the ability to build, test in a sandbox environment, and deploy AI agents that take action across connected systems. Every action runs under individual user permissions, not a shared account. Every step is traceable, auditable, and reversible: if an agent makes a mistake, it can be rolled back.

Key capabilities at a glance

Shared Memory: personal, team, and organizational memory that compounds over time

Trusted Answers: intent-aware search and consistent data answers. Same question, same answer, every time. Computer doesn't guess - it knows, and it shows its work.

Safe Actions: governed, auditable actions across your systems. Computer acts on your behalf with guardrails, so teams move faster without risk.

Multiplayer AI: shared live sessions for human-to-human, human-to-AI, and team-wide collaboration

Skills - reusable workflows that any team can build, share, and deploy. One person's expertise becomes everyone's capability. Agent Studio allows users to build and deploy AI agents with sandboxed testing, full audit trails, and rollback

Additional capabilities:

Text2SQL: analytical queries across structured data in plain language, no data analyst required

Connectors: Gmail, Outlook, Slack, Notion, Google Drive, Jira, Microsoft OneDrive, SharePoint, and any MCP-compatible tool

Usage-based pricing: that scales with adoption and not headcount

With the newest release of Computer, the above capabilities are all generally available today.

Results from customers in production

More than 250 organizations have Computer live in production, with over 1,000 users onboarded since launched in September 2025. Customers include BILL, HDFC Bank, and FAME, spanning financial services, aviation, retail, and technology.

The results Computer, by DevRev's customers are reporting speak for themselves. Customers Pebl and Uniphore are resolving 85% of support tickets without any human involvement. BILL has achieved around $5M in operational savings. India's largest airline went from kickoff to production in 14 days and selected Computer over Salesforce Agentforce in a head-to-head evaluation. A retail loyalty customer is saving $1.2M annually, with sales reps reclaiming six hours a week and the team reporting a 30% productivity boost. And FAME is saving users more than 10 hours a week, resolving tickets approximately 40% faster, and accelerating specific workflows by up to 75%.

Availability

Across web, mobile, and desktop. Use Computer from any device.

Inside the DevRev system of record apps. Existing DevRev customers can access Computer directly within their current workflow without switching surfaces.

Resources

Visit devrev.ai to learn more about the enterprise offering, book a demo, or start a free trial of Computer.

Usage-based pricing with plan and billing management are available at https://devrev.ai/pricing

About DevRev

DevRev is redefining enterprise software with AI-native solutions that unify siloed data and transform how teams and customers collaborate. Its patented technology takes structured and unstructured data from existing tools like Salesforce, Jira, and Zendesk, organizing it into a knowledge graph that powers conversational enterprise AI. With DevRev, businesses get precise answers, real-time analytics, and automated workflows to unlock unrealized value. Founded in 2020 and backed by Khosla Ventures and Mayfield, DevRev is led by co-founder and CEO Dheeraj Pandey, former co-founder and CEO of Nutanix and an Adobe board member, alongside co-founder Manoj Agarwal, former SVP of Engineering at Nutanix. Headquartered in Palo Alto, DevRev operates globally across eight offices.

Media relations contact:

DevRev@watersagency.com

Copyright 2026 GlobeNewswire, Inc.

Technical and regulatory hurdles make collocation unscalable for most developers

LONDON / HOUSTON / SINGAPORE - 21 May 2026 - The race to power artificial intelligence is pushing US data centre development to break the speed limit of grid development - creating significant risk for projects, markets and consumers, according to a new Wood Mackenzie report.

With grid transmission build-outs 5-10 years away and competitive pressure mounting, data centre operators are pursuing collocated generation and flexible interconnection models. Wood Mackenzie's latest Horizons report "Breaking the speed limit: Can US data centre development outpace grid development?" warns that these projects face far greater technical, regulatory and economic hurdles than the industry understands.

"The power sector is fixated on data centre flexibility, but that is not the end-game for grid operators or data centre operators," said Ben Hertz-Shargel, Global Head of Grid Transformation and Large Loads, Wood Mackenzie. "Firm grid service is the goal, backed by new transmission superhighways. But there is a lack of awareness throughout the power sector about the technical and regulatory risk confronting colocation projects, and the business risk of conditional interconnections."

The challenge is existential for deregulated markets. PJM, the Mid-Atlantic grid operator, has 78 gigawatts of committed data centre load against only 36 gigawatts of accredited generation capacity in its pipeline. In Texas, current market prices of $30-40 per megawatt-hour fall far below the $78-$100 needed to attract new gas generation. Wood Mackenzie's Accelerated case for data centre load growth entails 16.4 GW of gas capacity additions per year through 2035 to meet projected demand, despite only 4 GW per year from 2023 to 2025.

"Load growth and affordability are in direct opposition in the deregulated markets," said Chris Seiple, Vice Chairman, Energy Transition and Power and Renewables, Wood Mackenzie. "If prices rise to the level necessary to incentivise new generation, it will raise prices for all customers, prompting a political outcry."

To confront this, PJM is bifurcating its generation market - creating one elevated price tier for new resources contracted by large loads, and a lower tier for existing resources. The unintended consequence: existing gas and coal plants receiving lower capacity prices may retire, threatening reliability even as PJM struggles to bring new supply online. Texas, meanwhile, has no comparable plan to incentivise new grid-connected generation, and is trusting that competitive power markets will deliver the new supply.  That typically happens by prices rising to levels that attract new investment. 

Further regulatory intervention in deregulated markets is likely as affordability pressures mount, with potential knock-on consequences for existing asset valuations. The report warns that developers and investors should be prepared for market rule changes driven not by grid planning, but by political pressure.

Colocation, or a bring-your-own-generation (BYOG) approach, has been widely touted as a solution to grid constraints. With more than 90 GW of collocated generation now in US interconnection pipelines, it is clear the industry has placed a major bet on this model. However, the report finds that colocation is only achievable for the most sophisticated and well-capitalised hyperscalers, and that for many developers these projects will not materialise, making the model unscalable.

"Even for developers that see collocation as a viable bridging solution to grid power, the costs and technical challenges are formidable," said Hertz-Shargel. "Technology providers are only beginning to come to terms with this challenge, the mitigation of which is site-specific, making solutions hard to scale."

Key technical challenges include:

The near-instantaneous changes in AI power demand can damage reciprocating engines and gas turbines

Lithium-ion batteries can be used as a shock-absorber to prevent this, but risk running through their useful lifespan rapidly

The battery response time must be extremely short, relying on technology that has not been widely commercialised

The irregular manner in which AI cooling and GPU loads consume power introduces power harmonics, which if unfiltered cause equipment to overheat and degrade

These loads can also cause sub-synchronous oscillations, posing fundamental stability risk to local generators and to distant ones on the transmission system

The need to protect against downtime, moreover, exposes data centre companies to significant regulatory risk. Grid operators are fast-tracking rules for conditional interconnections to meet data centre companies' demand for speed-to-power, but their ultimate priority is grid reliability - and some recent decisions risk severely undercutting data centre business models.

"PJM's and SPP's rules are understood to give the regional grid priority rights over collocated generation," said Hertz-Shargel. "During shortages, data centres would be forced to reduce demand to their firm service level, even as their onsite generation was instructed to supply the grid. For some companies, this model is unworkable."

ERCOT, meanwhile, has been working with stakeholders to update its voltage and frequency ride-through requirements - rules designed to prevent data centres from reverting to backup power prematurely during minor grid disturbances. The risk is not hypothetical. In 2024, 60 data centres in Virginia dropped off the grid simultaneously following a minor disturbance, nearly causing a grid collapse.

Data centres in late-stage development are unlikely to be able to comply with the proposed changes, however, potentially requiring a site redesign and the purchase of new uninterruptible power supplies and other electrical equipment. With rules still being written and late-stage changes already threatening project viability, regulatory risk remains one of the most significant - and underappreciated - challenges facing the industry.

Underlying all of these challenges is also a fundamental question about cost allocation. Grid operators are planning close to $100 billion in transmission investments in part to support data centre load growth, including PJM ($11.8 billion), MISO ($30 billion+), ERCOT ($33 billion) and SPP ($8.6 billion). Without modification of traditional cost allocation rules, a significant portion of these regional investments could be spread across all existing ratepayers, not assigned specifically to the data centres driving their urgency. 

"Grid operators are positioning flexible interconnections as a stopgap, not a long-term solution," said Seiple. "The expectation - and often the requirement - is that transmission will eventually provide complete, firm service to large loads. That could cause costs to rise for existing customers if cost allocation methodologies aren't changed and if the data centre demand doesn't materialize as forecast." 

Read the entire report here.

ENDS

For further information please contact:  

Hla Myat Mon   

+65 8533 8860  

hla.myatmon@woodmac.com    

Mark Thomton  

+1 630 881 6885  

mark.thomton@woodmac.com     

Chris Boba  

+44 7408 841129  

chris.boba@woodmac.com     

Ang?lica Ju?rez   

+5256 4171 1980  

angelica.juarez@woodmac.com 

About Wood Mackenzie: 

Wood Mackenzie is the global leader in analytics, insights and proprietary data across the entire energy and natural resources landscape. For over 50 years our work has guided the decisions of the world's most influential energy producers, utilities companies, financial institutions and governments. Now, with the world's energy system more complex and interconnected than ever before, sector-specific views are no longer enough. That's why we've redefined what's possible with Intelligence Connected: the fusion of our unparalleled proprietary data with the sharpest analytical minds, all supercharged by Synoptic AI, to deliver a clear, interconnected view of the entire value chain. Our trusted team of 2,700 experts across 30 countries breaks siloes and connects industries, markets and regions across the globe to empower our customers to identify risk sooner, spot opportunity faster and make every decision with complete confidence. For more information, visit www.woodmac.com 

Mark Thomton

Wood Mackenzie

6308816885

mark.thomton@woodmac.com

Copyright 2026 GlobeNewswire, Inc.

Thursday, May 21st, 2026 - Paris

THE PARC DES PRINCES AS YOU'VE NEVER SEEN IT BEFORE

Paris Saint-Germain Legends, VIP Guests and Members of ALL Accor

gather for the "Dream Tournament"

An experience by ALL Accor

ALL Accor, Accor's booking platform and loyalty programme, took over the Parc des Princes on Monday, May 18, 2026, for the "Dream Tournament" - an immersive experience designed to allow guests step into the shoes of Paris Saint-Germain players, blending football, gastronomy, wellbeing, lifestyle and entertainment.

A DAY ON THE PITCH OF THE PARC DES PRINCES ALONGSIDE THOSE WHO MADE PARIS SAINT-GERMAIN HISTORY

For one day, ALL Accor transformed the iconic stadium of the Parisian club into a fully immersive playground bringing together public figures, content creators, Members of ALL Accor loyalty programme, media and a selected group of lucky contest winners around an experience offering a rare behind-the-scenes look into the world of elite football.

Reflecting the exclusive experiences made accessible through ALL Accor, more than 160 participants had the opportunity to live a day in the shoes of a Paris Saint-Germain player.

Entering through the players' tunnel, getting changed in the official locker rooms, preparing for matches alongside Paris Saint-Germain Legends, receiving coaching sessions and competing on one of the world's most legendary football pitches: every moment of the day was designed to immerse guests in the atmosphere of matchday while discovering the lifestyle, gastronomy and entertainment universe embodied by ALL Accor.

Divided into 16 teams and guided by 16 iconic Paris Saint-Germain figures, participants competed in a series of matches directly on the Parc des Princes pitch, in an atmosphere combining competition, emotion and transmission.

Pedro Miguel Pauleta, Javier Pastore, Ezequiel Lavezzi, Mamadou Sakho, Jay-Jay Okocha, Claude Mak?l?l?, Kevin Gameiro, Guillaume Hoarau, Ludovic Giuly, J?r?my M?nez, Nen?, Mario Yepes, Salvatore Sirigu, Cl?ment Chant?me, Gregory van der Wiel and Amara Simba all shared the pitch with guests throughout the day.

Alongside members of ALL Accor loyalty programme and Paris Saint-Germain Legends, several public personalities, content creators and talents also took part in the experience, including actor C?sar Domboy, artist Francis Essoua, content creators Matteo Sinet, Nourh?ne and Tony Czech, as well as Royal Monceau Raffles Paris pastry chef Yazid Ichemrahen (...).

SHOWCASING THE DIVERSITY OF BRANDS AVAILABLE ON ALL.COM

Throughout the day, ALL Accor brought the experience to life through several immersive activations inspired by the iconic worlds of the more than 45 brands within its portfolio.

Pitch-side, MGallery Collection notably offered a dedicated recovery and relaxation space for post-match downtime, while Novotel highlighted its food & beverage approach with a plant-based lunch focused on wellbeing and longevity, presented on-site by Alfie Steiner.

Designed as a true lifestyle interlude at the heart of the Parc des Princes, the experience continued with a reconnection dinner curated by M?venpick, bringing guests together in a more intimate atmosphere.

OFENBACH SETS THE PARC DES PRINCES ALIGHT

The experience extended into the evening with an after-party imagined by Sofitel and headlined by a DJ set from chart-topping duo Ofenbach.

Conceived as the natural continuation of the Dream Tournament, this musical moment also reflected ALL Accor's strong positioning within the world of music and entertainment, notably through its many cultural and music partnerships around the world (Accor Arena, Fever...).

ALL ACCOR AND PARIS SAINT-GERMAIN EXTEND THEIR PARTNERSHIP UNTIL 2030

ALL Accor and Paris Saint-Germain also took advantage of this emotion-filled day to officially announce the renewal of their partnership until 2030, reaffirming their shared ambition to continue creating ever more exclusive and immersive experiences for ALL Accor's more than 100 million members worldwide.

With this second edition of the Dream Tournament, ALL Accor confirms its ambition to deliver increasingly exclusive and emotional experiences at the crossroads of sport, culture, entertainment and hospitality. A way for the brand to turn loyalty into a true passport to the extraordinary, through unforgettable moments designed to inspire emotion, connection and lasting memories.

***

ALL ACCOR PRESS CONTACTS

Le Public Syst?me PR for ALL Accor

allaccor@lepublicsysteme.fr

+33 6 14 98 68 88

ALL Accor

Lucie Metzger - Global VP Brand Communication & Media

lucie.metzger@accor.com

Sophia Sabbani - Global PR Manager

Sophia.sabbani@consulting-for.accor.com

ABOUT ALL Accor

ALL Accor is a booking platform and loyalty programme embodying the Accor promise during and beyond the hotel stay. Through the ALL.com website and app, customers can access an unrivalled choice of stays from more than 45 Accor brands in 110 countries, always at the best price. The ALL Accor loyalty programme gives members access to a wide range of rewards, services and experiences, along with over 100 renowned partners. ALL Accor supports its members daily, enabling them to live their passions with over 7,000 events worldwide each year: local activities, chef masterclasses, major sports tournaments and the most eagerly awaited concerts. ALL Accor is the loyalty programme preferred by travellers.

Discover ALL Accor: ALL.com

About Paris Saint-Germain

Founded in 1970 and winner of the UEFA Champions League in 2025, Paris Saint-Germain is the most successful club in France and a leading force in European football. Since 2011, under the leadership of Qatar Sports Investments (QSI), the Club has established itself as a premier multi-sport institution (men's and women's football, handball, judo, esports), driven by values of excellence, teamwork and surpassing limits. As part of this momentum, the Club reached a major

milestone in its sporting development in 2024 with the inauguration of the Paris Saint-Germain Campus, an ultramodern complex located in Poissy.

Deeply rooted in Paris, Paris Saint-Germain draws on the creative energy of the capital and contributes to its global influence, with a presence in nearly 100 countries and a community of 500 million fans. Both a committed institution serving its local communities and a dynamic global brand, the Club has developed a unique model at the intersection of sport, culture and lifestyle, making it the Club of the New Generation.

Attachment

CP POST DREAM TOURNAMENT (1)

Copyright 2026 GlobeNewswire, Inc.

Cardiovascular and Respiratory medicines to be supplied in Malaysia and the Philippines

Signing Ceremony_Strategic Partnership Agreement Between Hanmi & Organon

SEOUL, South Korea, May 21, 2026 (GLOBE NEWSWIRE) -- Hanmi Pharmaceutical announced that it has signed a supply agreement with global healthcare company Organon to export three combination medicines for the Malaysian and Philippine markets, expanding the companies' partnership in Southeast Asia.

Under the agreement, Hanmi will supply three finished combination products in the cardiovascular and respiratory therapeutic areas, while Organon will be responsible for marketing, distribution, and sales in the local markets. The two companies plan to pursue phased regulatory approvals and product launches in Malaysia and the Philippines, with the potential to expand their collaboration over the mid to long term.

Organon, established in 2021 is a global healthcare company with a portfolio of over 70 products across a range of therapeutic areas. Through a deep commercial ability and trusted manufacturing network, Organon brings these important medicines and devices to patients when and where they need them in over 140 markets, including Southeast Asia.

Hanmi Pharmaceutical has previously expanded its global presence through partnerships with multinational pharmaceutical companies. The current agreement with Organon builds on Hanmi's experience in global collaborations and is expected to support the company's commercial expansion in the Southeast Asian market.

Southeast Asia is widely regarded as a rapidly growing pharmaceutical market driven by population growth and the increasing prevalence of chronic diseases. In particular, demand for combination therapies is rising as the number of patients with chronic conditions such as hypertension continues to increase.

"At Organon, we are committed to improving access to medicines that address the greatest health needs in the communities we serve," said Mazen Altaruti, President, Organon Emerging Markets. "This partnership with Hanmi reflects our shared focus on expanding treatment options for patients in Malaysia and the Philippines and advancing more equitable access to care across the region."

Sean Hwang, CEO of Hanmi Pharmaceutical, said, "Hanmi will continue accelerating its global expansion with our diverse portfolio of combination therapies, which represent one of the company's core strengths. Through our collaboration with Organon, we aim to improve treatment accessibility for patients in Southeast Asia."

*Contact info:

Official Websites: www.hanmipharm.com, www.linkedin.com/company/hanmipharm

innovation@hanmi.co.kr, +82-02-410-0467

Copyright 2026 GlobeNewswire, Inc.

A strategic synergy of style, innovation, and environmental respect to drive the evolution of international yachting

MONACO, May 21, 2026 (GLOBE NEWSWIRE) -- North Sails Apparel announces its role as the Official Technical Clothing Partner of the Yacht Club de Monaco (YCM), one of the leading institutions driving innovation and excellence in international yachting. This collaboration brings together two maritime icons defined by a shared pursuit of sporting excellence, technical innovation, and a deep-rooted commitment to ocean conservation.

A Shared Vision of Excellence

Yacht Club de Monaco stands as a prestigious reference in international yachting, an exclusive private institution where tradition meets the visionary leadership of its President, HSH Prince Albert II. Housed in its iconic, Lord Foster-designed Clubhouse at the heart of Port Hercule, the YCM is the definitive hub for the global maritime elite. With a legacy of excellence and a forward-looking approach to sustainability, the Club provides the ideal environment for North Sails Apparel to showcase its high-performance DNA.

At the heart of the partnership lies a shared vision: authentic performance, technical credibility, and a forward‑looking approach to the sport. Together with YCM, North Sails Apparel expands its footprint across the Mediterranean's top sporting landscape, strengthening its role as the premium brand for sailors worldwide.

"Being a partner of Yacht Club de Monaco is a significant recognition of our positioning within the international sailing," says Cedric Georges, CEO of North Sails Apparel. "Standing alongside an institution that embodies tradition, excellence, and vision allows us to bring our technical credibility and modern, performance‑driven vision to a highly authoritative stage. This partnership is both symbolic and strategic, placing North Sails Apparel at the heart of a community that lives and breathes the sea."

"As part of our collective approach Monaco, Capital of Advanced Yachting, we are proud to partner with North Sails Apparel, a benchmark in the world of sailing, recognised for its technical expertise and long-standing commitment to performance," says Bernard d'Alessandri, General Secretary and General Manager of the Yacht Club de Monaco. "Through our flagship initiatives, such as the Monaco Classic Week - La Belle Classe (8-11 September 2027), the Primo Cup-UBS Trophy (4-7 March 2027), the Monaco Energy Boat Challenge (8-11 July 2026) and the SEA Index?, we bring to life the complementarity between maritime heritage, innovation and environmental responsibility. This partnership with North Sails Apparel strengthens this dynamic, with a shared ambition to support the sustainable evolution of our sport and the wider industry."

A Synergy of Design and Presence

Central to this partnership is a natural integration of technical expertise and lifestyle. Moving beyond a traditional sponsorship, the collaboration focuses on product development, with North Sails Apparel designing dedicated collections for the Yacht Club de Monaco's boutique and key events. Function‑led design defines the project. Each garment, from official uniforms to technical sportswear, balances protection, reliability, and comfort. Using advanced materials and responsible production processes, North Sails Apparel equips YCM staff and athletes shaped by the evolving expectations of the sailing world.

More than a technical partnership, this union represents a shared dedication to the future of yachting. The collaboration between North Sails Apparel and Yacht Club de Monaco marks a decisive convergence of heritage and technical evolution. It is a synergy where maritime tradition meets advanced engineering, designed for a community that values both prestige and performance. By aligning their shared expertise, both institutions are committed to equipping the next generation of sailors with the tools and the vision to navigate an evolving landscape, driven by a profound respect for the sea.

Copyright 2026 GlobeNewswire, Inc.